All Clarivate websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.
Roche has synthesized pyruvate dehydrogenase kinase 1 (PDK1) inhibitors reported to be useful for the treatment of systemic lupus erythematosus, psoriasis, inflammatory bowel diseases, idiopathic pulmonary fibrosis, chronic obstructive pulmonary disease and cancer.
Vertex Pharmaceuticals Inc. has received clearance from the FDA for its IND application for VX-522, a messenger ribonucleic acid (mRNA) therapy targeted at treating the underlying cause of cystic fibrosis (CF).
Sionna Therapeutics Inc. has received FDA clearance of its IND application for SION-638, a small molecule designed to target the first nucleotide-binding domain (NBD1) of the cystic fibrosis transmembrane conductance regulator (CFTR) protein. A phase I study is now dosing healthy volunteers.
Hyloris Pharmaceuticals SA has announced the development of HY-083, a new proprietary intranasal formulation of a TRPV1 agonist to treat idiopathic rhinitis. Hyloris' treatment approach is to activate and depolarize TRPV1 receptors leading to restoration of a normal function of the nasal mucosa.
Suzhou Suncadia Biopharmaceuticals Co. Ltd. and Jiangsu Hengrui Medicine Co. Ltd. have synthesized isoquinolone compounds acting as phosphodiesterase PDE3A and/or PDE4 inhibitors reported to be useful for the treatment of asthma, chronic obstructive pulmonary disease (COPD), sepsis, nephritis, diabetes, allergic rhinitis, allergic conjunctivitis and rheumatic diseases.
Boehringer Ingelheim Pharma GmbH & Co. KG has divulged imidazo[4,5-d]pyridazinonyl derivatives acting as transient receptor potential cation channel subfamily A member 1 (TRPA1) antagonists reported to be useful for the treatment of cough, fibrosis, respiratory tract inflammation and idiopathic pulmonary fibrosis.
Humanwell Healthcare (Group) Co. Ltd. has synthesized dihydropyrimidoisoquinolinone derivatives acting as G protein-coupled receptor 84 (GPR84) antagonists reported to be useful for the treatment of chronic obstructive pulmonary disease (COPD), rheumatoid arthritis, inflammatory bowel disease, pulmonary fibrosis, vasculitis, infections, metabolic and endocrine disorders, among others.
Angion Biomedica Corp. has synthesized prodrugs of terevalefim acting as hepatocyte growth factor (HGF) mimetics and reported to be useful for the treatment of renal ischemia-reperfusion and lung injury.
Saniona AB has completed preclinical development with SAN-903 and is ready to start the regulatory process for entering phase I trials either alone or together with a partner. SAN-903 is a novel, potential first-in-class medicine based on inhibition of the calcium-activated potassium ion channel KCa3.1.
RSS
